Painkilling, Antiseptic Prep Pad Provides Fast Relief from Needle Pain
Spectra Medical Devices, Wilmington, Mass., a global manufacturer of made-to-spec procedural needles and a distributor of complementary medical instruments, supplies, and pharmaceuticals, has announced NUMSTAT™, a pain-relieving, antiseptic, and anesthetic prep pad.
NUMSTAT was developed by physicians to help people with a fear of needle sticks and pain, which can cause a delay in necessary testing and medical care. The prep pad is designed to clean the surface of the skin, reduce the risk of infection, and quickly relieve the pain of needle sticks.
Users can apply the prep pad in advance of a needle stick by gently rubbing it onto the skin for 60 seconds and letting it dry. The advanced application helps to reduce pain at the site of the needle stick.
For more information, visit num-stat.com.
Real-Time, Two-Way Medication Integration with Electronic Health Record Platform
Enclara Pharmacia has launched a bidirectional medication interface with MatrixCare. This integration between Enclara’s E3 Pro™ platform and MatrixCare’s electronic health record (EHR) delivers real-time, two-way communication between systems, enabling hospice clinicians to save time and provide quality patient care through secure access to the most current and accurate information about patient medications.
With a standard medication interface, staff enters a medication into the hospice EHR, which transmits to Enclara. Staff then uses Enclara’s E3 Pro application to order the medication, either through electronic prescribing to a local pharmacy or Enclara’s national fulfillment centers. This process supports accurate claims adjudication and provides full visibility to Enclara pharmacists for 24/7 symptom management consultations and drug utilization reviews required by Medicare.
This enhanced integration also simplifies regulatory compliance under Medicare’s Hospice Change Request (CR) 8358 requirements. With the real-time two-way flow of information between Enclara and MatrixCare’s platforms, the time-consuming process of manual reconciliation to ensure an accurate health record can be reduced or eliminated.
For more information, visit enclarapharmacia.com.
New Telemedicine Platform Enhances Quality of Life
EMA Telemed, Chevy Chase, Md., a new telemedicine platform, has launched and is specifically designed to enhance patient outcomes, reduce health care costs, and generate new revenue streams for health care facilities.
This innovative new platform supports real-time vital sign monitoring through secure video consultations using medically approved sensors, features a user-friendly scheduling tool with automatic reminders for streamlined appointment management, and offers robust data security with encrypted storage and detailed daily health reports.
The pilot program is an excellent opportunity for directors of health care facilities to explore how telemedicine can be seamlessly integrated into their operations, providing significant benefits without any initial investment.
For more information, visit ematelemed.com/contact.
New Technology Successful in Reducing Urgent Threat on Contaminated Surfaces
Results from a study presented at the Society for Healthcare Epidemiology of America annual conference indicate Dry Hydrogen Peroxide (DHP™) from Synexis effectively reduces Candida auris (C. auris) contamination on surfaces. C. auris, a type of fungus, can cause severe infections in hospitalized patients and nursing home residents. C. auris cases continue to rise in the United States, up 318 percent since 2018. Antimicrobial resistance to C. auris is also on the rise, causing significant challenges for health care providers. Data report 90 percent of C. auris isolates are resistant to at least one antifungal, while 30 percent are resistant to at least two antifungals, creating challenges for infection control.
The study was designed to assess the presence of C. auris environmental contamination in multiple clinical units and to evaluate the efficacy of DHP™, a continuous supplemental technology, and its exposure on C. auris contamination. The research was conducted in a large tertiary care center where multiple patients were either infected or colonized with C. auris.
Prior to the installation of DHP™, 70 percent of surfaces sampled in active C. auris patient rooms tested positive
for the presence of C. auris. The same surfaces were sampled during the month after installation of DHP™, and the proportion of samples testing positive for C. auris decreased to 16.7 percent.
For more information, visit synexis.com.